Skip Navigation



Annals of Oncology Advance Access published online on April 8, 2005
Annals of Oncology, doi:10.1093/annonc/mdi179
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/6/893    most recent
mdi179v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nilsson, P. J.
Right arrow Articles by Glimelius, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nilsson, P. J.
Right arrow Articles by Glimelius, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received September 28, 2004
Accepted January 7, 2005

Original article

Tumour budding detected by laminin-5 {gamma}2-chain immunohistochemistry is of prognostic value in epidermoid anal cancer

P. J. Nilsson 1*, C. Rubio 2, C. Lenander 1, G. Auer 2, and B. Glimelius 3

1 Centre of Gastrointestinal Disease, Ersta Hospital, Stockholm, Sweden
2 Department of Oncology and Pathology, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
3 Department of Oncology and Pathology, Karolinska University Hospital, SE 171 76 Stockholm, Sweden; Department of Oncology, Radiology and Clinical Immunology, Akademiska Sjukhuset, SE 751 85 Uppsala, Sweden

* To whom correspondence should be addressed.
P. J. Nilsson, E-mail: per.nilsson{at}ersta.se


  Abstract

Background:: Markers for guidance with regard to individual prognosis and treatment planning are sought in epidermoid anal cancer. This study assessed the prognostic and predictive value of tumour budding.

Patients and methods:: From a population-based consecutive series of patients who were prospectively recorded, it was possible to investigate 209 (76%) of the pretreatment biopsies. Immunohistochemistry with a monoclonal antibody for the {gamma}2 chain of laminin-5 was used to detect tumour budding (defined as dissociated single cancer cells or clusters of up to five cells).

Results:: Tumour budding was detected in 104 (50%) of the 209 samples. No significant correlation was found between tumour budding and clinicopathological characteristics. Patients with tumour budding had a statistically significantly better 5-year overall survival rate compared with patients lacking tumour budding (74% versus 64%, P <0.05). Albeit not statistically significant, other outcome variables such as tumour-specific survival, recurrence after initial complete response and rate of distant metastases, were all in favour of patients with tumour budding. Multivariate analysis reveals tumour budding as an independent positive prognostic factor.

Conclusions:: Tumour budding detected by laminin-5 immunohistochemistry may be of prognostic value in the treatment of epidermoid anal cancer. However, further studies are needed to clarify the possible clinical implications.

Keywords: anus neoplasm; radiotherapy; prognosis; tumour budding; laminin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. M. Guess, B. J. LaFleur, B. L. Weidow, and V. Quaranta
A Decreased Ratio of Laminin-332 {beta}3 to {gamma}2 Subunit mRNA is Associated with Poor Prognosis in Colon Cancer
Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1584 - 1590.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.